Christine L Chan1, Laura Pyle2, Tim Vigers1,2, Philip S Zeitler1, Kristen J Nadeau1. 1. Department of Pediatrics, Pediatric Endocrinology, Children's Hospital Colorado and University of Colorado Anschutz Medical Center, Aurora, Colorado 80045, USA. 2. Department of Biostatistics, Colorado School of Public Health, Aurora, Colorado 80045, USA.
Abstract
CONTEXT: Early glucose abnormalities in people with cystic fibrosis (PwCF) are commonly detected by continuous glucose monitoring (CGM). Relationships between these CGM abnormalities and oral glucose tolerance testing (OGTT) in PwCF have not been fully characterized. OBJECTIVE: This work aimed to determine the relationship between CGM and common OGTT-derived estimates of β-cell function, including C-peptide index and oral disposition index (oDI) and to explore whether CGM can be used to screen for OGTT-defined prediabetes and cystic fibrosis-related diabetes (CFRD). METHODS: PwCF not on insulin and healthy controls aged 6 to 25 years were enrolled in a prospective study collecting OGTT and CGM. A subset underwent frequently sampled OGTTs (fsOGTT) with 7-point glucose, insulin, and C-peptide measurements. Pearson correlation coefficient was used to test the association between select CGM and fsOGTT measures. Receiver operating curve (ROC) analysis was applied to CGM variables to determine the cutoff optimizing sensitivity and specificity for detecting prediabetes and CFRD. RESULTS: A total of 120 participants (controls = 35, CF = 85), including 69 with fsOGTTs, were included. CGM coefficient of variation correlated inversely with C-peptide index (Cpeptide30-Cpeptide0/Glucose30-Glucose0) (r = -0.45, P < .001) and oDIcpeptide (C-peptide index)(1/cpep0) (r = -0.48, P < .0001). In PwCF, CGM variables had ROC - areas under the curve ranging from 0.43 to 0.57 for prediabetes and 0.47 to 0.6 for CFRD. CONCLUSION: Greater glycemic variability on CGM correlated with reduced β-cell function. However, CGM performed poorly at discriminating individuals with and without OGTT-defined CFRD and prediabetes. Prospective studies are now needed to determine how well the different tests predict clinically relevant nonglycemic outcomes in PwCF.
CONTEXT: Early glucose abnormalities in people with cystic fibrosis (PwCF) are commonly detected by continuous glucose monitoring (CGM). Relationships between these CGM abnormalities and oral glucose tolerance testing (OGTT) in PwCF have not been fully characterized. OBJECTIVE: This work aimed to determine the relationship between CGM and common OGTT-derived estimates of β-cell function, including C-peptide index and oral disposition index (oDI) and to explore whether CGM can be used to screen for OGTT-defined prediabetes and cystic fibrosis-related diabetes (CFRD). METHODS: PwCF not on insulin and healthy controls aged 6 to 25 years were enrolled in a prospective study collecting OGTT and CGM. A subset underwent frequently sampled OGTTs (fsOGTT) with 7-point glucose, insulin, and C-peptide measurements. Pearson correlation coefficient was used to test the association between select CGM and fsOGTT measures. Receiver operating curve (ROC) analysis was applied to CGM variables to determine the cutoff optimizing sensitivity and specificity for detecting prediabetes and CFRD. RESULTS: A total of 120 participants (controls = 35, CF = 85), including 69 with fsOGTTs, were included. CGM coefficient of variation correlated inversely with C-peptide index (Cpeptide30-Cpeptide0/Glucose30-Glucose0) (r = -0.45, P < .001) and oDIcpeptide (C-peptide index)(1/cpep0) (r = -0.48, P < .0001). In PwCF, CGM variables had ROC - areas under the curve ranging from 0.43 to 0.57 for prediabetes and 0.47 to 0.6 for CFRD. CONCLUSION: Greater glycemic variability on CGM correlated with reduced β-cell function. However, CGM performed poorly at discriminating individuals with and without OGTT-defined CFRD and prediabetes. Prospective studies are now needed to determine how well the different tests predict clinically relevant nonglycemic outcomes in PwCF.
Authors: M Stumvoll; A Mitrakou; W Pimenta; T Jenssen; H Yki-Järvinen; T Van Haeften; W Renn; J Gerich Journal: Diabetes Care Date: 2000-03 Impact factor: 19.112
Authors: Kalie L Tommerdahl; John T Brinton; Tim Vigers; Kristen J Nadeau; Philip S Zeitler; Christine L Chan Journal: Pediatr Diabetes Date: 2019-10-02 Impact factor: 4.866
Authors: A Leclercq; B Gauthier; V Rosner; L Weiss; F Moreau; A A Constantinescu; R Kessler; L Kessler Journal: J Cyst Fibros Date: 2013-12-17 Impact factor: 5.482
Authors: Nathaniel J Hart; Radhika Aramandla; Gregory Poffenberger; Cody Fayolle; Ariel H Thames; Austin Bautista; Aliya F Spigelman; Jenny Aurielle B Babon; Megan E DeNicola; Prasanna K Dadi; William S Bush; Appakalai N Balamurugan; Marcela Brissova; Chunhua Dai; Nripesh Prasad; Rita Bottino; David A Jacobson; Mitchell L Drumm; Sally C Kent; Patrick E MacDonald; Alvin C Powers Journal: JCI Insight Date: 2018-04-19
Authors: Aliye Uc; Alicia K Olivier; Michelle A Griffin; David K Meyerholz; Jianrong Yao; Maisam Abu-El-Haija; Katherine M Buchanan; Oriana G Vanegas Calderón; Marwa Abu-El-Haija; Alejandro A Pezzulo; Leah R Reznikov; Mark J Hoegger; Michael V Rector; Lynda S Ostedgaard; Peter J Taft; Nick D Gansemer; Paula S Ludwig; Emma E Hornick; David A Stoltz; Katie L Ode; Michael J Welsh; John F Engelhardt; Andrew W Norris Journal: Clin Sci (Lond) Date: 2015-01 Impact factor: 6.124
Authors: Jill Brodsky; Shayne Dougherty; Ramkrishna Makani; Ronald C Rubenstein; Andrea Kelly Journal: Diabetes Care Date: 2011-01-12 Impact factor: 19.112
Authors: Kalie L Tommerdahl; John T Brinton; Tim Vigers; Melanie Cree-Green; Philip S Zeitler; Kristen J Nadeau; Christine L Chan Journal: J Cyst Fibros Date: 2020-09-11 Impact factor: 5.482
Authors: Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134